Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
You may also be interested in...
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans.
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.